Gujarat Themis Biosyn Ltd Share Price (GUJTHEM)

GTBL was established in Dec.81 as a public limited company. Starting with the manufacturing of antibiotic erythromycin, it obtained licence in 1990 to produce bulk drugs like rifampicin, cephalexin, and griseofulvin with their formulations. From 1991, it faced several issues, thus making it a BIFR (Board of Industrial and Financial Reconstruction) case. It was then taken over by a group of investors – Lyka Labs, Themis Chemicals, Kopran, Cadila, and Yuhan Corporation (South Korea). In 1995-1996, they increased their paid up capital to Rs 11.60 crores after allotment of 350000 equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions. This was followed by an increase in the installed capacity of rifamycinS to 90 mtpa and expansion of rifampicin to maximum capacity of 120 mtpa. They further launched a wide range of antituberculosis products and other antibiotics. They are focused on further diversifying and expanding their existing products and capacities with the scope to reduce production costs and increase turnover.

Revenue: ₹37.74Cr as on March 2025 (Q4 FY25)
Net Profit: ₹12.00Cr as on March 2025 (Q4 FY25)
Listing date: 01 Jun, 1995
Chairperson Name: Dinesh S Patel